title: Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1.
abstract: The signaling pathways whereby glucose and hormonal secretagogues regulate insulin-secretory function, gene transcription, and proliferation of pancreatic beta-cells are not well defined. We show that in the glucose-responsive beta-cell line INS-1, major secretagogue-stimulated signaling pathways converge to activate 44-kDa mitogen-activated protein (MAP) kinase. Thus, glucose-induced insulin secretion was found to be associated with a small stimulatory effect on 44-kDa MAP kinase, which was synergistically enhanced by increased levels of intracellular cAMP and by the hormonal secretagogues glucagon-like peptide-1 and pituitary adenylate cyclase-activating polypeptide. Activation of 44-kDa MAP kinase by glucose was dependent on Ca2+ influx and may in part be mediated by MEK-1, a MAP kinase kinase. Stimulation of Ca2+ influx by KCl was in itself sufficient to activate 44-kDa MAP kinase and MEK-1. Phorbol ester, an activator of protein kinase C, stimulated 44-kDa MAP kinase by both Ca(2+)-dependent and -independent pathways. Nerve growth factor, independently of changes in cytosolic Ca2+, efficiently stimulated 44-kDa MAP kinase without causing insulin release, indicating that activation of this kinase is not sufficient for secretion. In the presence of glucose, however, nerve growth factor potentiated insulin secretion. In INS-1 cells, activation of 44-kDa MAP kinase was partially correlated with the induction of early response genes junB, nur77, and zif268 but not with stimulation of DNA synthesis. Our findings suggest a role of 44-kDa MAP kinase in mediating some of the pleiotropic actions of secretagogues on the pancreatic beta-cell.
authors.affiliation: INSERM, Unité 145, Faculté de Médecine, Nice, France.
authors.forename: M
authors.initials: M
authors.lastname: Frödin
authors.forename: N
authors.initials: N
authors.lastname: Sekine
authors.forename: E
authors.initials: E
authors.lastname: Roche
authors.forename: C
authors.initials: C
authors.lastname: Filloux
authors.forename: M
authors.initials: M
authors.lastname: Prentki
authors.forename: C B
authors.initials: CB
authors.lastname: Wollheim
authors.forename: E
authors.initials: E
authors.lastname: Van Obberghen
mesh_terms: D002118:Calcium / Q000378:metabolism; D002166:Camptothecin / Q000031:analogs & derivatives / Q000494:pharmacology; D002460:Cell Line; D003600:Cytosol / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis / Q000187:drug effects; D004789:Enzyme Activation; D005786:Gene Expression Regulation; D017781:Genes, Immediate-Early; D005947:Glucose / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000378:metabolism*; D009414:Nerve Growth Factors / Q000494:pharmacology*; D011189:Potassium Chloride / Q000494:pharmacology; D011494:Protein Kinases / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D007328:Insulin; D009414:Nerve Growth Factors; D011189:Potassium Chloride; D004247:DNA; D011494:Protein Kinases; D005947:Glucose; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium; D002166:Camptothecin